HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients
Abstract The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified. HER2 positive rates and hazard...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-86556-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571767431888896 |
|---|---|
| author | Boqiang Lyu Shidi Zhao Hui Wang Shouping Gong Biyuan Wang |
| author_facet | Boqiang Lyu Shidi Zhao Hui Wang Shouping Gong Biyuan Wang |
| author_sort | Boqiang Lyu |
| collection | DOAJ |
| description | Abstract The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified. HER2 positive rates and hazard ratios (HR) for overall survival (OS) were combined using Metaprop. The prevalence of HER2 + MBC was 10.0% (95% CI: 8.0-13.0%). Subgroup analyses showed that 7% (95% CI: 2.0-14.0%) had HER2 + protein overexpression. 10% of MBC patients had HER2 + overexpression and/or gene amplification. Asian MBC patients had the highest HER2 + incidence of 17% (95% CI: 12.0-22.0%). The prevalence of HER2 positive MBC fluctuated widely from 2001 to 2015 and then stabilized at 10%. HER2 positivity was significantly correlated with worse OS than negative ones (HR = 1.92, 1.47–2.51). The proportion of HER2 + MBC was inconsistent with the results for the intrinsic HER2-enriched subtype. Altered genes in HER2 + MBC, such as ERBB2, AGO2, RECQL4, and CLTC, were not detected in HER2-MBC. Genomic analysis revealed differences between the patients with HER2 + MBC and those with HER2 + FBC. The percentage of HER2 + MBC was slightly lower than that of women. Multiple approaches may be needed to jointly assess HER2 status in MBC. |
| format | Article |
| id | doaj-art-00a958ed8992470f873afa57f224d5ea |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-00a958ed8992470f873afa57f224d5ea2025-02-02T12:18:59ZengNature PortfolioScientific Reports2045-23222025-01-0115111410.1038/s41598-025-86556-0HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patientsBoqiang Lyu0Shidi Zhao1Hui Wang2Shouping Gong3Biyuan Wang4Department of Neurosurgery, the Second Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Neurosurgery, the Second Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong UniversityAbstract The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified. HER2 positive rates and hazard ratios (HR) for overall survival (OS) were combined using Metaprop. The prevalence of HER2 + MBC was 10.0% (95% CI: 8.0-13.0%). Subgroup analyses showed that 7% (95% CI: 2.0-14.0%) had HER2 + protein overexpression. 10% of MBC patients had HER2 + overexpression and/or gene amplification. Asian MBC patients had the highest HER2 + incidence of 17% (95% CI: 12.0-22.0%). The prevalence of HER2 positive MBC fluctuated widely from 2001 to 2015 and then stabilized at 10%. HER2 positivity was significantly correlated with worse OS than negative ones (HR = 1.92, 1.47–2.51). The proportion of HER2 + MBC was inconsistent with the results for the intrinsic HER2-enriched subtype. Altered genes in HER2 + MBC, such as ERBB2, AGO2, RECQL4, and CLTC, were not detected in HER2-MBC. Genomic analysis revealed differences between the patients with HER2 + MBC and those with HER2 + FBC. The percentage of HER2 + MBC was slightly lower than that of women. Multiple approaches may be needed to jointly assess HER2 status in MBC.https://doi.org/10.1038/s41598-025-86556-0Human epidermal growth factor receptorImmunohistochemistryFluorescence in situ hybridization |
| spellingShingle | Boqiang Lyu Shidi Zhao Hui Wang Shouping Gong Biyuan Wang HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients Scientific Reports Human epidermal growth factor receptor Immunohistochemistry Fluorescence in situ hybridization |
| title | HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients |
| title_full | HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients |
| title_fullStr | HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients |
| title_full_unstemmed | HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients |
| title_short | HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients |
| title_sort | her2 expression and pathway status in male breast cancer patients results of an integrated analysis among 6 150 patients |
| topic | Human epidermal growth factor receptor Immunohistochemistry Fluorescence in situ hybridization |
| url | https://doi.org/10.1038/s41598-025-86556-0 |
| work_keys_str_mv | AT boqianglyu her2expressionandpathwaystatusinmalebreastcancerpatientsresultsofanintegratedanalysisamong6150patients AT shidizhao her2expressionandpathwaystatusinmalebreastcancerpatientsresultsofanintegratedanalysisamong6150patients AT huiwang her2expressionandpathwaystatusinmalebreastcancerpatientsresultsofanintegratedanalysisamong6150patients AT shoupinggong her2expressionandpathwaystatusinmalebreastcancerpatientsresultsofanintegratedanalysisamong6150patients AT biyuanwang her2expressionandpathwaystatusinmalebreastcancerpatientsresultsofanintegratedanalysisamong6150patients |